NASDAQ:TENX | Free Cash Flow | TENAX THERAPEUTICS, INC.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2010-07-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$9.31M
2025-12-31-$13.42M
2025-03-31-$6.97M
2024-12-31-$3.53M
2024-03-31-$5.17M
2023-12-31-$1.18M
2023-03-31-$1.72M$1,241.00-$1.73M
2022-12-31-$1.69M-$4,000.00-$1.69M-66.41%
2022-03-31-$2.94M$6,323.00-$2.94M
2021-12-31-$2.77M$1,698.00-$2.77M
2021-03-31-$3.22M$0.00-$3.22M
2020-12-31-$1.99M$3,490.00-$1.99M
2020-03-31-$2.67M$0.00-$2.67M
2019-12-31-$1.73M$0.00-$1.73M
2019-03-31-$2.13M$3,574.00-$2.14M-132.08%
2018-12-31-$1.2M$1,788.00-$1.2M
2018-03-31-$1.56M$3,105.00-$1.56M-130.90%
2017-12-31-$1.28M$1.00-$1.28M
2017-03-31-$4.04M$3,272.00-$4.04M-123.35%
2016-12-31-$3.11M$0.00-$3.11M
2016-03-31-$3.32M$2,884.00-$3.32M
2015-07-31-$3.84M$16,688.00-$3.86M
2015-04-30-$1.63M$0.00-$1.63M
2015-03-31-$2.54M$0.00-$2.54M
2014-07-31-$1.98M$0.00-$1.98M
2014-04-30-$2.98M$0.00-$2.98M
2013-07-31-$1.56M$0.00-$1.56M
2013-04-30-$1.44M$2,267.00-$1.44M
2012-07-31-$1.61M$12,719.00-$1.63M
2012-04-30-$1.42M$6,281.00-$1.43M
2011-07-31-$2.05M$0.00-$2.05M
2011-04-30-$1.75M$53,315.00-$1.8M-63.30%
2010-07-31-$2.61M-$88,906.00-$2.7M-90.01%

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$35.8M
2024-12-31-$14.81M
2023-12-31-$5.9M
2022-12-31-$11.39M$2,323.00-$11.39M-103.10%
2021-12-31-$10.86M$5,252.00-$10.86M
2020-12-31-$9.27M$3,490.00-$9.28M
2019-12-31-$7.56M$3,574.00-$7.56M
2018-12-31-$5.5M$7,595.00-$5.51M
2017-12-31-$12.14M$4,537.00-$12.15M
2016-12-31-$15.87M$2,884.00-$15.87M
2015-04-30-$9.75M$4,234.00-$9.75M
2014-04-30-$9.26M$9,804.00-$9.27M
2013-04-30-$4.92M$17,199.00-$4.94M
2012-04-30-$8.28M$17,652.00-$8.3M
2011-04-30-$8.4M$240,824.00-$8.64M-82.73%

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.